ABL Diagnostics (FR001400AHX6) (“ABLD” or the “Company”) announced today that, since August 2023, three dispositions, for a total of 59,651 of its ordinary shares, have been reported to ONDE, the central system of information filing of the Financial Markets Authority (AMF), and are publicly available on the website of the AMF decision and notification database (https://bdif.amf-france.org/ in).
The transfers of blocks of ordinary shares were carried out by its parent company, Advanced Biological Laboratories (ABL), a private company headquartered in Luxembourg. ABL is the main shareholder of the ABLD Company, with more than 99% of the shares.
Mr. Ronan Boulmé, GRC Director of the ABL Group, said: “These transactions – 0.37% of the total ordinary shares – are in line with our commitment to the AMF to divest up to thirty percent (30%). of our common stock in order to create a float of ABLD shares. He added: “This is an objective pursued with effort and accompanied by discussions of partnerships in progress. The recent transfers of blocks of shares mark the beginning of a strategy for ABL Diagnostics which should allow it to embark on its next phase growth and development. These investments will support ABL Diagnostics’ continued efforts to develop and commercialize cutting-edge diagnostic solutions in collaboration with strategic partners around the world.”